Zai Lab Analyst Ratings
Zai Lab Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/26/2023 | 209.45% | Goldman Sachs | $82.47 → $73.34 | Maintains | Buy |
| 10/17/2023 | 170.04% | JP Morgan | $67 → $64 | Maintains | Overweight |
| 10/09/2023 | 195.36% | Cantor Fitzgerald | → $70 | Reiterates | Overweight → Overweight |
| 09/18/2023 | 195.36% | Cantor Fitzgerald | → $70 | Reiterates | Overweight → Overweight |
| 08/10/2023 | 195.36% | Cantor Fitzgerald | → $70 | Initiates Coverage On | → Overweight |
| 06/12/2023 | 163.71% | B of A Securities | $75 → $62.5 | Maintains | Buy |
| 05/11/2023 | 448.52% | Citigroup | $138 → $130 | Maintains | Buy |
| 03/16/2023 | 195.36% | JP Morgan | $79 → $70 | Maintains | Overweight |
| 11/18/2022 | 233.33% | JP Morgan | $96 → $79 | Maintains | Overweight |
| 11/11/2022 | 435.86% | Citigroup | $199 → $127 | Maintains | Buy |
| 08/09/2022 | 739.66% | Citigroup | $193 → $199 | Maintains | Buy |
| 05/12/2022 | 714.35% | Citigroup | $198 → $193 | Maintains | Buy |
| 05/11/2022 | 300.84% | SVB Leerink | $101 → $95 | Maintains | Outperform |
| 04/21/2022 | 326.16% | SVB Leerink | $102 → $101 | Maintains | Outperform |
| 04/04/2022 | 372.57% | JP Morgan | $136 → $112 | Maintains | Overweight |
| 03/02/2022 | 330.38% | SVB Leerink | $194 → $102 | Maintains | Outperform |
| 12/15/2021 | 473.84% | JP Morgan | $189 → $136 | Maintains | Overweight |
| 11/11/2021 | 815.61% | Citigroup | $222 → $217 | Maintains | Buy |
| 11/10/2021 | 718.57% | SVB Leerink | $200 → $194 | Maintains | Outperform |
| 10/12/2021 | — | Bernstein | Initiates Coverage On | → Market Perform | |
| 06/01/2021 | 752.32% | SVB Leerink | $192 → $202 | Maintains | Outperform |
| 04/14/2021 | 710.13% | SVB Leerink | $183 → $192 | Maintains | Outperform |
| 02/03/2021 | 697.47% | SVB Leerink | $107 → $189 | Maintains | Outperform |
| 09/10/2020 | 300.84% | SVB Leerink | $93 → $95 | Maintains | Outperform |
| 12/30/2019 | 254.43% | Citigroup | $65 → $84 | Maintains | Buy |
| 09/04/2019 | — | China Renaissance | Initiates Coverage On | → Buy | |
| 07/05/2019 | — | Macquarie | Initiates Coverage On | → Outperform | |
| 01/29/2019 | 46.41% | Credit Suisse | → $34.7 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年10月26日 | 209.45% | 高盛 | $82.47→$73.34 | 维护 | 买 |
| 10/17/2023 | 170.04% | 摩根大通 | $67→$64 | 维护 | 超重 |
| 10/09/2023 | 195.36% | 康托·菲茨杰拉德 | →$70 | 重申 | 超重→超重 |
| 09/18/2023 | 195.36% | 康托·菲茨杰拉德 | →$70 | 重申 | 超重→超重 |
| 2023年08月10日 | 195.36% | 康托·菲茨杰拉德 | →$70 | 开始承保 | →超重 |
| 2023/06/12 | 163.71% | B of A证券 | $75→$62.5 | 维护 | 买 |
| 2023年05月11日 | 448.52% | 花旗集团 | $138→$130 | 维护 | 买 |
| 03/16/2023 | 195.36% | 摩根大通 | $79→$70 | 维护 | 超重 |
| 2022年11月18日 | 233.33% | 摩根大通 | $96→$79 | 维护 | 超重 |
| 2022年11月11日 | 435.86% | 花旗集团 | $199→$127 | 维护 | 买 |
| 08/09/2022 | 739.66% | 花旗集团 | $193→$199 | 维护 | 买 |
| 2022年05月12日 | 714.35% | 花旗集团 | $198→$193 | 维护 | 买 |
| 2022年05月11日 | 300.84% | SVB Leerink | $101→$95 | 维护 | 跑赢大盘 |
| 04/21/2022 | 326.16% | SVB Leerink | $102→$101 | 维护 | 跑赢大盘 |
| 04/04/2022 | 372.57% | 摩根大通 | $136→$112 | 维护 | 超重 |
| 03/02/2022 | 330.38% | SVB Leerink | $194→$102 | 维护 | 跑赢大盘 |
| 2021年12月15日 | 473.84% | 摩根大通 | $189→$136 | 维护 | 超重 |
| 2021年11月11日 | 815.61% | 花旗集团 | $222→$217 | 维护 | 买 |
| 2021年11月10日 | 718.57% | SVB Leerink | $200→$194 | 维护 | 跑赢大盘 |
| 10/12/2021 | - | 伯恩斯坦 | 开始承保 | →市场表现 | |
| 06/01/2021 | 752.32% | SVB Leerink | $192→$202 | 维护 | 跑赢大盘 |
| 04/14/2021 | 710.13% | SVB Leerink | $183→$192 | 维护 | 跑赢大盘 |
| 02/03/2021 | 697.47% | SVB Leerink | $107→$189 | 维护 | 跑赢大盘 |
| 09/10/2020 | 300.84% | SVB Leerink | $93→$95 | 维护 | 跑赢大盘 |
| 2019年12月30日 | 254.43% | 花旗集团 | $65→$84 | 维护 | 买 |
| 2019年09月04日 | - | 中国文艺复兴 | 开始承保 | →购买 | |
| 2019年05月07日 | - | 麦格理 | 开始承保 | →跑赢大盘 | |
| 2019年01月29日 | 46.41% | 瑞士信贷 | →$34.7. | 开始承保 | →跑赢大盘 |
What is the target price for Zai Lab (ZLAB)?
再鼎医药(ZLAB)的目标价是多少？
The latest price target for Zai Lab (NASDAQ: ZLAB) was reported by Goldman Sachs on October 26, 2023. The analyst firm set a price target for $73.34 expecting ZLAB to rise to within 12 months (a possible 209.45% upside). 10 analyst firms have reported ratings in the last year.
高盛于2023年10月26日报道了再鼎医药(纳斯达克代码：ZLAB)的最新目标价。这家分析公司将目标价定为73.34美元，预计ZLAB将在12个月内上涨(可能上涨209.45%)。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Zai Lab (ZLAB)?
分析师对再鼎医药的最新评级是多少？
The latest analyst rating for Zai Lab (NASDAQ: ZLAB) was provided by Goldman Sachs, and Zai Lab maintained their buy rating.
高盛对再鼎医药(纳斯达克代码：ZLAB)的最新分析师评级为买入，再鼎医药维持买入评级。
When is the next analyst rating going to be posted or updated for Zai Lab (ZLAB)?
下一次分析师对再鼎医药的评级会在什么时候发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Zai Lab, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Zai Lab was filed on October 26, 2023 so you should expect the next rating to be made available sometime around October 26, 2024.
分析师在进行了广泛的研究后得出了股票评级，这些研究包括查阅公开的财务报表，与再鼎医药的高管和客户交谈，以及收听财报电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。对再鼎医药的上一次评级是在2023年10月26日提交的，所以你应该预计下一次评级将在2024年10月26日左右公布。
Is the Analyst Rating Zai Lab (ZLAB) correct?
分析师对再鼎医药的评级正确吗？
While ratings are subjective and will change, the latest Zai Lab (ZLAB) rating was a maintained with a price target of $82.47 to $73.34. The current price Zai Lab (ZLAB) is trading at is $23.70, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的再鼎医药评级维持不变，目标价在82.47美元至73.34美元之间。再鼎医药目前的股价为23.7美元，超出了分析师的预期区间。